M-CSF–driven osteoclast expansion creates a self‑reinforcing niche threshold that blocks erythropoietic recovery in aging bone marrow
Hypothesis Chronic elevation of M-CSF in the aged marrow niche triggers a bistable switch: osteoclast precursors expand, secrete further M-CSF, and lock the microenvironment into an osteoclast‑dominant state that physically and chemically excludes erythroid progenitors, even when EPO signaling remains intact.
Mechanistic basis
- Positive feedback loop – EPO acting on CD115+ osteoclast precursors raises M-CSF ~2‑fold within 16 h [1]. Elevated M-CSF promotes osteoclast survival and proliferation, which in turn produces additional M-CSF (autocrine/paracrine). This loop can generate a threshold beyond which osteoclast occupancy exceeds a critical niche volume.
- Niche exclusion – Expanded osteoclasts occupy endosteal niches and secrete proteases (e.g., cathepsin K) that remodel extracellular matrix, reducing fibronectin and VCAM‑1 availability required for erythroid progenitor adhesion and proliferation.
- Iron sequestration – Osteoclast‑derived inflammation elevates hepcidin via IL‑6 signaling, further limiting iron for erythropoiesis [2]. Thus, the niche shift compounds intrinsic erythroid defects through both spatial and metabolic mechanisms.
- Preserved EPOR responsiveness – When osteoclast expansion is genetically blocked (EPOR deletion in myeloid lineage) erythropoiesis is maintained despite niche remodeling [3], indicating erythroid progenitors retain EPO sensitivity if physical competition is relieved.
Testable predictions
- Threshold detection – In aged mice, M-CSF concentration in marrow interstitial fluid will show a bimodal distribution; values above ~X pg/mL correlate with >30 % osteoclast surface occupancy and a sharp drop in TER119+ progenitors.
- Feedback interruption – Short‑term administration of an M-CSF neutralizing antibody will reduce osteoclast numbers by >40 % within 48 h, lower marrow M-CSF levels below the threshold, and restore erythroid colony‑forming unit‑erythroid (CFU‑E) output to youthful levels without altering EPOR expression.
- Hysteresis – After M-CSF blockade is withdrawn, aged marrow will remain in the erythroid‑favorable state for at least two weeks if osteoclast numbers stay below the threshold, demonstrating a bistable switch rather than a simple linear relationship.
- Stem cell bias independence – HSCs isolated from aged mice subjected to M-CSF blockade will exhibit lymphoid‑myeloid output similar to young HSCs when transplanted into niche‑neutral recipients, indicating that observed erythroid bias is niche‑driven, not intrinsic.
Experimental approach
- Measure marrow M-CSF by ELISA in young (3 mo) and aged (24 mo) mice; correlate with osteoclast surface (TRAP staining) and erythroid progenitor flow cytometry.
- Intervene with anti‑M-CSF antibody (or small‑molecule CSF1R inhibitor) administered intraperitoneally every 3 days for 2 weeks; assess niche composition, serum hepcidin, and hemoglobin.
- Rescue experiments: add recombinant M-CSF to blockade‑treated aged marrow ex vivo to test whether progenitor suppression is reversible.
- Mathematical modeling: fit ODEs describing EPO‑EPOR‑M-CSF‑osteoclast interactions to empirical data to identify the critical M-CSF threshold that predicts niche state transitions.
If the threshold exists and its disruption reverses age‑associated anemia, the hypothesis would reframe therapeutic focus from global EPO supplementation to targeted niche rebalancing via M-CSF pathway modulation.